IDEAYA Biosciences Inc. (IDYA)
NASDAQ: IDYA
· Real-Time Price · USD
19.57
0.15 (0.77%)
At close: May 28, 2025, 3:59 PM
20.25
3.50%
After-hours: May 28, 2025, 07:42 PM EDT
0.77% (1D)
| Bid | 18.25 |
| Market Cap | 1.71B |
| Revenue (ttm) | 7M |
| Net Income (ttm) | -306.31M |
| EPS (ttm) | -3.65 |
| PE Ratio (ttm) | -5.36 |
| Forward PE | -6.29 |
| Analyst | Buy |
| Ask | 21 |
| Volume | 777,210 |
| Avg. Volume (20D) | 1,368,693 |
| Open | 19.45 |
| Previous Close | 19.42 |
| Day's Range | 19.29 - 20.17 |
| 52-Week Range | 13.45 - 44.42 |
| Beta | 0.25 |
About IDYA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IDYA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IDYA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+0.34%
IDEAYA Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
10 months ago
-3.37%
IDEAYA Biosciences shares are trading lower after the company priced a $263 million public offering of 228,572 common shares and pre-funded warrants at $35 per share.
2 weeks ago · seekingalpha.com
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849Ideaya Biosciences, Inc. is advancing darovasertib in a phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma patients, with mPFS data expected by end of 2025. Ideaya plans a phase 3 study of ...
